Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVASTIN vs PREZCOBIX PED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Darumavir is an HIV-1 protease inhibitor that inhibits the cleavage of HIV-1 Gag-Pol polyproteins, resulting in non-infectious immature viral particles. Cobicistat is a CYP3A inhibitor that boosts darunavir exposure without contributing to antiviral activity.
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
Treatment of HIV-1 infection in pediatric patients weighing at least 15 kg in combination with other antiretroviral agents,FDA-approved for pediatric patients with HIV-1
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
PREZCOBIX PED is a pediatric formulation; adult dosing is not applicable. For adults, the equivalent product is PREZCOBIX (darunavir/cobicistat) fixed-dose combination: 800 mg/150 mg orally once daily with food.
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Darunavir: ~15 hours (with cobicistat). Cobicistat: ~3-4 hours.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Darumavir is extensively metabolized by CYP3A; cobicistat is a mechanism-based inhibitor of CYP3A and is metabolized by CYP3A and to a minor extent by CYP2D6.
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Darunavir: ~80% fecal (mostly as parent), ~14% renal (3% unchanged). Cobicistat: ~86% fecal, ~8% renal.
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
Darunavir: ~95% bound to alpha-1-acid glycoprotein (AAG). Cobicistat: ~97-98% bound to plasma proteins.
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
Darunavir: Vd ~88 L (1.3 L/kg for 70 kg adult). Cobicistat: Vd ~144 L (2.1 L/kg for 70 kg adult).
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
Darunavir: ~82% (with cobicistat, relative to ritonavir-boosted). Cobicistat: ~70%.
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
For darunavir/cobicistat: not recommended in patients with Cr Cl <70 m L/min due to cobicistat component. No dose adjustment required for Cr Cl ≥70 m L/min.
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). Not recommended in moderate impairment (Child-Pugh Class B) due to lack of data. Use with caution in mild impairment (Child-Pugh Class A); no dose adjustment required.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
Pediatric dosing for PREZCOBIX PED (darunavir/cobicistat) is weight-based: for body weight ≥40 kg: 800 mg/150 mg orally once daily with food. For weight 30 to <40 kg: 675 mg/150 mg orally once daily with food. For weight 15 to <30 kg: 600 mg/150 mg orally once daily with food. For weight <15 kg: not recommended.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
No specific dose adjustment for elderly patients; use standard dosing. Monitor renal function, as age-related decline may affect clearance of cobicistat component. Consider alternative regimen if Cr Cl <70 m L/min.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
None
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Hepatotoxicity: monitor hepatic function; discontinue if signs of hepatitis or elevated transaminases with rash or systemic symptoms occur,Severe skin reactions: including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS); discontinue if severe rash develops,Sulfonamide allergy: darunavir contains a sulfonamide moiety; use with caution in patients with known sulfonamide allergy,Drug interactions: cobicistat is a CYP3A inhibitor; contraindicated with drugs highly dependent on CYP3A for clearance,Diabetes mellitus: new onset or exacerbation may occur,Hemophilia: increased bleeding risk in patients with hemophilia A or B,Fat redistribution and immune reconstitution syndrome
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
Hypersensitivity to darunavir, cobicistat, or any component of the formulation,Co-administration with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, amiodarone, colchicine in renal/hepatic impairment, ergot derivatives, lomitapide, lovastatin, oral midazolam, sildenafil for pulmonary arterial hypertension, simvastatin, triazolam),Co-administration with St. John's Wort,Severe hepatic impairment (Child-Pugh Class C)
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
Administer with food to enhance absorption. No specific dietary restrictions, but avoid grapefruit juice as it may alter drug levels. Do not take with St. John's wort (herbal supplement). Avoid alcohol in patients with liver disease.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
PREZCOBIX PED (darunavir/cobicistat) is contraindicated in pregnancy due to the risk of preterm delivery, low birth weight, and potential for neural tube defects based on animal studies. First trimester exposure associated with increased risk of congenital anomalies; second and third trimester exposure linked to fetal growth restriction and metabolic disturbances.
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
Breastfeeding is not recommended for HIV-infected mothers to avoid HIV transmission. Darunavir is excreted in human milk at low concentrations; cobicistat is likely excreted. M/P ratio not established.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
No dose adjustment required based on pharmacokinetic studies; however, consider increased monitoring for virologic failure due to potential altered drug levels. Avoid use in pregnancy if alternatives exist.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
Prezcobix PED is a fixed-dose combination of darunavir (protease inhibitor) and cobicistat (pharmacokinetic enhancer) for pediatric patients. Do not use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for hepatotoxicity, especially in patients with HBV/HCV coinfection. Renal impairment: cobicistat decreases creatinine secretion, leading to increased serum creatinine without affecting GFR; no dose adjustment needed but monitor renal function. Contraindicated with drugs that are strong CYP3A inducers (e.g., rifampin, St. John's wort) or substrates with narrow therapeutic index (e.g., alfuzosin, ergot derivatives). Administer with food to enhance absorption.
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
Take exactly as prescribed; do not skip doses to reduce risk of resistance.,Must be taken with food to ensure adequate absorption.,Inform your doctor of all medications, including over-the-counter drugs and herbal supplements, due to potential interactions.,This medicine does not cure HIV; it reduces viral load and can still transmit HIV to others. Use condoms and avoid sharing needles.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain, or unusual fatigue.,Do not use with St. John's wort, rifampin, or certain other drugs; ensure your doctor knows your full medication list.,If you have hemophilia, note that protease inhibitors may increase bleeding risk.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVASTIN vs PREZCOBIX PED, answered by our medical review team.
AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. PREZCOBIX PED is a HIV Antiviral (Protease Inhibitor Combination) that works by Darumavir is an HIV-1 protease inhibitor that inhibits the cleavage of HIV-1 Gag-Pol polyproteins, resulting in non-infectious immature viral particles. Cobicistat is a CYP3A inhibitor that boosts darunavir exposure without contributing to antiviral activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVASTIN and PREZCOBIX PED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. The standard adult dose of PREZCOBIX PED is: PREZCOBIX PED is a pediatric formulation; adult dosing is not applicable. For adults, the equivalent product is PREZCOBIX (darunavir/cobicistat) fixed-dose combination: 800 mg/150 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVASTIN and PREZCOBIX PED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. PREZCOBIX PED is classified as Category C. PREZCOBIX PED (darunavir/cobicistat) is contraindicated in pregnancy due to the risk of preterm delivery, low birth weight, and potential for neural tube defects based on animal st. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.